Cancer Vaccine Halves Melanoma Recurrence Risk as ASCO 2026 Unveils New Precision Drugs

Five-year follow-up data from the KEYNOTE-942 trial, unveiled at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, confirmed that a personalised mRNA cancer vaccine, when added to the immunotherapy pembrolizumab, reduces the risk of recurrence or death in advanced melanoma by 49%. Developed by Moderna and Merck, the therapy — intismeran autogene — tailors its genetic payload to the unique mutations of a patient’s tumour. Of those receiving the combination, 68.8% remained cancer-free at five years, compared with 49.1% for pembrolizumab alone, according to data published in the Journal of Clinical Oncology. Oncologists in Europe and the United States described the result as a milestone, validating mRNA technology beyond COVID-19.

Equally striking were results in cancers that have long defied conventional treatment. In head and neck tumours no longer responding to standard therapies, a bispecific antibody called amivantamab — delivered by simple subcutaneous injection — shrank lesions in more than a third of patients in an early-phase trial, with some experiencing complete radiological clearance. German and Italian researchers, presenting the OrigAMI-4 data, emphasised the drug’s triple mechanism of action, blocking EGFR and another growth pathway. Separately, a targeted pill against RAS-mutant pancreatic cancer, daraxonrasib, doubled overall survival compared with standard chemotherapy in a phase 3 trial. Brazilian and U.S. investigators hailed the outcome as a rare advance against one of oncology’s most lethal diagnoses, noting it is the first agent to selectively inhibit the RAS signalling network rather than bluntly killing dividing cells.

Precision medicine also marked a win for breast cancer patients: the British-led Optima trial suggested that a genomic test could safely spare thousands of women from chemotherapy. Women with low-risk scores appeared to fare just as well with hormone therapy alone, a finding set to reshape care pathways in national health systems. Meanwhile, regulators are moving quickly. The European Commission granted marketing authorisation to tarlatamab for extensive-stage small cell lung cancer, based on a 40% reduction in mortality in the DeLLphi-304 study, offering a novel immunotherapy option where few exist.

Viewed from London or Rome, the ASCO 2026 proceedings reflect a broader pivot toward less toxic, more tailored therapies. Researchers also flagged provocative signals from lifestyle studies — including the interplay of obesity, fasting, and immune response — that could further fine-tune care. For all the excitement, analysts caution that the high cost of mRNA manufacturing and bispecific antibodies will test healthcare budgets, particularly in middle-income countries. Yet the sheer breadth of advances, spanning four tumour types and multiple drug classes, signals that oncology is entering an era in which the maxim ‘harder therapy, better outcomes’ is finally being retired.